Un-audited Financial Results for the Quarter and Half Year ended September 30, 2026

Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 27th October, 2026 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results

Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 is enclosed.

The Board of Directors of the company at their meeting held today i.e. October, 27, 2026 inter alia, considered and approved the Un-audited Financial Results for the quarter and half year ended on September 30, 2026 and took on record Limited Review Report thereon pursuant to Regulation 33 of Listing Regulations (Enclosed herewith)

The Board of Directors of the Company at their meeting held on Friday, October 27, 2026, inter alia, considered & approved Unaudited Standalone & Consolidated Financial Results of the Company for the second quarter & half year ended September 30, 2026

The Unaudited Financial Results for the Half Year Ended September 30, 2026.

Unaudited Financial Result for the half year ended September 30, 2026.

Onesource Specialty Pharma Limited has submitted to the Exchange the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

Financial Results 30.09.2026

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated Financial Results for the half year ended 30th September, 2026. (The copy of Un-Audited Standalone & Consolidated Financial results along with Limited Review Report